Covid-19 Technology Deployment (CoviTeD)

An Acceleration Program sponsored by SPMCIL CSR


AIC-CCMB has initiated several activities including support for development and validation of novel Covid-19 innovations by start-ups and MSMEs. Our goal is to support and rapidly deploy diagnostics and therapeutics through the participation of research institutes, industries, policy maker and incubators.

As the pandemic wages in the country with devastating consequences, AIC-CCMB is inviting entrepreneurs and innovators with promising technologies to join our Covid-19 Technology Deployment (CoviTeD) Acceleration Program. A CSR initiative of Security Printing and Minting Corporation of India Limited (SPMCIL), the CoviTeD program aim to provide high impact mentoring, financial, regulatory and marketing support to take these products and technologies to market.

Focus Area

  • Medical devices for management of covid-19 patients
  • Quantifiable tests for ancillary markers of Covid-19
  • Rapid Diagnostics
  • Drugs & Therapeutics
  • Sterilization and hygiene
  • Logistics for biologicals
  • Post-mortem management

Who can apply

We invite applications from startups and innovators with technologies/products for managing COVID-19, who are looking for clinical validations, certification etc.

  1. The applicant must be a start-up/company registered in India, with at least 51% Indian shareholding, and with a competent team in place, preferably with a domain expertise.
  2. Association with the incubator (resident or virtual mode) would be preferred.
  3. Individual innovators with promising technologies can be supported.
  4. Startup should be less than 10 years in existence.
  5. Proof of Concept or prototype stage. Start-ups with products at commercialization stage can also apply.
  6. The applicant startup should have developed clear product to market fit, customer discovery with clarity on intended customers and value propositions for its targeted customers.
  7. Preferably at revenue stage or has raised fund earlier.
  8. MSMEs who need scale- up, quality assurance and regulatory support can apply.
  9. Preferably, ready to deploy product within a few of weeks.
  10. Products requiring approval from competent authorities.

Startups whose technologies/products are deemed to be of huge importance in our ongoing fight against COVID, will be recommended for NIDHI-Seed Support Scheme of DST.

Acceleration Program:

Duration: 16 weeks

Program content:

  • Module-1: Validation of solution and scope
  • Module-2: Markets - Primary Market Analysis, TAM
  • Module-3: Refining the solution with customer centric approach, Validating Value Proposition
  • Module-4: Regulatory clearances and IP filing
  • Module-5: Pricing, Customer buying analysis, Competitor analysis, Product Life-cycle analysis
  • Module-6: Establishing Supply chain, Launch strategy, Sales & Positioning.

Each module involves prototyping, validation at CSIR- CCMB, interaction with end user and mentoring from best industry leaders.

What you get

  • Two awardees - Winner get seed fund/ award of Rs 15 lacs, runner up gets seed fund/ award of Rs 10 lacs.
  • Access to validation and analytical services at CCMB, an ICMR (Indian Council of Medical Research) lab designated to validate the non-US FDA, and non-EUA/CE-IVD approved kits for Covid-19 testing.
  • A chance to work with scientists directly working on SARS-CoV-2 genomics.
  • Accelerated deployment early deployment and commercialisation through partners and policy makers.
  • Strong ecosystem connects for higher value creation and recognition.
  • A chance to secure additional funding under National Initiative for Developing and Harnessing Innovations -Seed Support System (NIDHI-SSS) by National Science & Technology Entrepreneurship Development Board (NSTEDB), Department of Science & Technology (DST), GoI and other partners.
  • Expert guidance and handholding for Up-scaling Production, quality assurance, validation studies as well as regulatory & IP Consultancy for manufacturing diagnostic kits, medical devices and therapeutics for SARS-CoV-2.
  • Partnerships with key stakeholders like National & International technology partners, policy makers & mentors.

Important Dates

  • May 17, 2021 - Call opens
  • May 31, 2021 - Call closes
  • June 4, 2021 - Shortlisting based on project relevance and readiness.
  • June 10, 2021 - Pitch day (Final selections by CSR committee members)